LLT1 on tumor cells interact with an NK-cell inhibitory receptor, NKRP1A (CD161), leading to the inhibition of NK-cell-mediated cytotoxicity of tumor cells [32,33,35,49,50,51,52,53]. Here, CLEC2D is linked to neoplasm.